Search
- Apr 30
James Field describes how LabGenius is using machine intelligence to design the next generation of multispecific antibodies
LabGenius is combining in silico design and automation to optimize antibody design, oftentimes with a non-obvious result.
- Apr 30
GSK's Emma Walmsley on the company's pipeline, business development, AI, UK life sciences, and more
In a wide ranging interview, Emma Walmsley discusses GSK's R&D activities in its four main areas of focus.
- Apr 29
Prokarium's CEO explains how the company is harnessing bacteria as a therapy, and in the future as a deliverer of therapies
Kristen Albright describes Prokarium's bladder cancer program, which went into the clinic earlier this year, and a platform (including a...
- Apr 29
Quell Therapeutics' CEO describes the process of using genetically modified Tregs for immune dysregulation conditions
Iain McGill discusses the company's clinical liver transplant program, as well as IBD and type 1 diabetes programs.
- Apr 29
e-therapeutics CEO Ali Mortazavi on the capital markets in London and his company's computational forward RNAi platform
He explains the decision to withdraw e-therapeutics from London AIM and describes the HepNet and GalOmic platforms that have produced the...
- Apr 29
Penn Medicine's Dr. Donald O'Rourke describes advances being seen today in using CAR-T against glioblastoma
He says that intrathecal administration as well as taking a dual target approach are key factors that have led to improvements over...